DEINOVE EXPANDS ITS INNOVATIVE ANTIBIOTIC PORTFOLIO BY SIGNING A LICENSE OPTION AGREEMENT WITH REDX PHARMA

March 22, 2018
DEINOBIOTICS/DEINOVE

Montpellier, 22 March 2018 (8:00 am CET) – DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria, announces having signed a license option agreement with the British company REDX PHARMA (AIM: REDX) for the acquisition of their first-in-class1 anti-infective program, Novel Bacterial Topoisomerase Inhibitor (NBTI), targeting Gram-negative infections.

Press Release avalaible here: